MB8.F Moberg Pharma AB (publ)
- Market cap
- EUR 41.8M
- P/E
- -
- P/B
- 0.68x
- ROE
- -1.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MB8.F undervalued?
Graham numberThe Graham number of Moberg Pharma AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Moberg Pharma AB (publ) fundamental analysis
No fundamental analysis for Moberg Pharma AB (publ) yet.
Moberg Pharma AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Full company profileMoberg Pharma AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Moberg Pharma AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 207K | 0.00 | 9.81M | 13.5M | 21.4M |
| Gross Profit | 0.00 | 207K | 0.00 | 6.32M | 7.68M | 14.1M |
| Operating Income | -19.7M | -20.5M | -27.9M | -325M | -28.0M | -13.2M |
| EBITDA | - | -16.9M | -23.1M | -18.9M | -22.2M | -8.39M |
| Net Income | 7.49M | -15.7M | -21.1M | -255M | -27.2M | -9.09M |
| EPS | 1.09 | -1.07 | -0.75 | -5.46 | -0.58 | -0.19 |
| Balance Sheet | ||||||
| Total Assets | 451M | 564M | 635M | 706M | 682M | 681M |
| Total Liabilities | 16.8M | 30.8M | 24.0M | 19.3M | 17.0M | 18.5M |
| Shareholders' Equity | 434M | 534M | 611M | 687M | 665M | 663M |
| Cash & Short-term Investments | 102M | 125M | 59.9M | 293M | 231M | 212M |
| Cash Flow | ||||||
| Operating Cash Flow | -15.3M | -16.8M | -33.2M | -16.5M | -17.5M | -13.4M |
| Capital Expenditure | 31.3M | 68.1M | 124M | 73.6M | 43.2M | 21.8M |
| Free Cash Flow | -46.6M | -84.9M | -157M | -90.0M | -60.7M | -35.3M |
| Ratios | ||||||
| ROE | 1.7% | -2.9% | -3.5% | -37.1% | -4.1% | -1.4% |
| ROA | 1.7% | -2.8% | -3.3% | -36.1% | -4.0% | -1.3% |
| Net Profit Margin | - | -7,589.4% | - | -2,600.3% | -201.2% | -42.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Moberg Pharma AB (publ) dividends
Moberg Pharma AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on May 24, 2023.
Who owns Moberg Pharma AB (publ)
- Insiders 10.91%
- Institutions 27.20%
- Public & others 61.89%
- Shares outstanding 47.2M
- Free float 37.9M
Moberg Pharma AB (publ) company profile
- Company name
- Moberg Pharma AB (publ)
- Ticker
- MB8.F
- ISIN
- SE0020353928
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 5
- Fiscal year end
- December
- Address
- Gustavslundsvägen 42, Bromma, Sweden, 167 51
- Phone
- 46 8 52 23 07 00
- Website
- mobergpharma.se
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Moberg Pharma AB (publ) management
7- Ms. Anna Ljung BA, M.Sc.Chief Executive Officer · born 1980
- Ms. Marie MobergCo-Founder
- Mr. Mark BeveridgeVice President of Finance & CFO · born 1978
- Dr. Amir Tavakkol Ph.D.Chief Scientific Officer · born 1956
- Gunilla WengströmSenior Director of Sales & Marketing
- Ms. Helena JanssonChief Business Officer & Vice CEO · born 1975
- Vaidrius NavikasChief Medical Officer · born 1966